Abstract
Cancer remains a difficult disease to manage because of the deregulation of numerous signaling pathways that are associated with its development and progression. One such pathway is the phosphoinositide 3-kinase (PI3K) – protein kinase B (Akt) - mammalian target of rapamycin (mTOR) signaling network, which is known to be associated with poor prognosis in many human cancers. Targeted inhibition of this signaling network in vitro, in vivo and in clinics has suggested this to be an effective strategy for the inhibition of cancer cells’ proliferation and metastases. Towards this end, the use of natural agents for therapeutic intervention has attracted renewed interest because of their non-toxic effects as well as their ability to modulate multiple pathways. Investigations involving isoflavones have suggested a potent anticancer activity of these compounds against multiple factors in the PI3K/Akt/mTOR pathway. In addition to their use as therapeutic agents against various cancers, there is evidence to support the role of isoflavones in potentiation of radiation therapy as well as the anticancer action of other conventional therapeutic drugs. In this review article, we discuss our current understanding of the regulation of PI3K/Akt/mTOR signaling pathways by isoflavones, which could be responsible for their observed in vitro and in vivo activity against human cancers.
Keywords: Isoflavones, anticancer therapy, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), genistein, deguelin, sensitization.
Anti-Cancer Agents in Medicinal Chemistry
Title:Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Volume: 13 Issue: 7
Author(s): Aamir Ahmad, Bernhard Biersack, Yiwei Li, Dejuan Kong, Bin Bao, Rainer Schobert, Subhash B. Padhye and Fazlul H. Sarkar
Affiliation:
Keywords: Isoflavones, anticancer therapy, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), genistein, deguelin, sensitization.
Abstract: Cancer remains a difficult disease to manage because of the deregulation of numerous signaling pathways that are associated with its development and progression. One such pathway is the phosphoinositide 3-kinase (PI3K) – protein kinase B (Akt) - mammalian target of rapamycin (mTOR) signaling network, which is known to be associated with poor prognosis in many human cancers. Targeted inhibition of this signaling network in vitro, in vivo and in clinics has suggested this to be an effective strategy for the inhibition of cancer cells’ proliferation and metastases. Towards this end, the use of natural agents for therapeutic intervention has attracted renewed interest because of their non-toxic effects as well as their ability to modulate multiple pathways. Investigations involving isoflavones have suggested a potent anticancer activity of these compounds against multiple factors in the PI3K/Akt/mTOR pathway. In addition to their use as therapeutic agents against various cancers, there is evidence to support the role of isoflavones in potentiation of radiation therapy as well as the anticancer action of other conventional therapeutic drugs. In this review article, we discuss our current understanding of the regulation of PI3K/Akt/mTOR signaling pathways by isoflavones, which could be responsible for their observed in vitro and in vivo activity against human cancers.
Export Options
About this article
Cite this article as:
Ahmad Aamir, Biersack Bernhard, Li Yiwei, Kong Dejuan, Bao Bin, Schobert Rainer, Padhye B. Subhash and Sarkar H. Fazlul, Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990117
DOI https://dx.doi.org/10.2174/18715206113139990117 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Formulation, Characterisation and In vitro Cytotoxic Effect of Lens culinaris Medikus Seeds Extract Loaded Chitosan Microspheres
Current Molecular Pharmacology Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Current Cancer Drug Targets Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Bioprospecting for Functionally-Proficient Potential Probiotics
Current Nutrition & Food Science The Role of Heat Shock Proteins in Cisplatin Resistance
Anti-Cancer Agents in Medicinal Chemistry Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology